Global Special Situations & Strategy, SR Services Ltd

David Lepper

Global Special Situations & Strategy

SR Services Ltd

SR Services provides Strategic Knowledge and Solutions services for Family Offices and Corporate Business. 

We deliver this via advisory services, strategic planning, opportunity analysis/sourcing, as well as solution implementation. 

Whilst, we create intellectual discipline and operational leverage for your projects or daily activities, our ultimate objective is to empower whilst enhancing your decision making. 

Strategic Knowledge and Solutions

Cross Asset Strategy

Growth as a style has been the “norm” for years, is the “norm” about to end? The continued strategies by Central Bank’s towards a “lower for longer stance around interest rates”, extended the underperformance of value for most of 2020. However, with the value/growth investment style ratio at 20-year lows, we present 27 names which hold characteristics worthy of further review.

Growth as a style has been the “norm” for years, is the “norm” about to end? The continued strategies by Central Bank’s towards a “lower for longer stance around interest rates”, extended the underperformance of value for most of 2020. However, with the value/growth investment style ratio at 20-year lows, we present 27 names which hold characteristics worthy of further review. 

Screening the Silk Road: Q1 2021 All Cap Screening - Free Cashflow (FCF)

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>Neuberger <a href="https://prtimes.jp/main/html/rd/p/000000018.000059963.html" target="_blank" rel="noopener">issued a letter</a> concerning the unfair terms of the <a href="https://www.smartkarma.com/entities/alsok-co-ltd" target="_blank" data-smartkarma-citation="entities:14181:1" rel="noopener">Alsok (2331 JP)</a> and Carlyle offer for <a href="https://www.smartkarma.com/entities/nippon-dry-chemical-co-ltd" target="_blank" data-smartkarma-citation="entities:13528:1" rel="noopener">Nippon Dry Chemical (1909 JP)</a>. The first closing date is 29 June.</li>
<li>Neuberger, the second-largest shareholder, highlights six issues with the tender offer. While Neuberger’s criticisms have merit, the Board could credibly refute most of them. </li>
<li>The probability of a bump is low, as Neuberger cannot block the tender, the offer is attractive on several measures, and ALSOK/Carlyle can use the playbook to counter activists.  </li>
</ul>


Neuberger issued a letter concerning the unfair terms of the Alsok (2331 JP) and Carlyle offer for Nippon Dry Chemical (1909 JP). The first closing date is 29 June.
Neuberger, the second-largest shareholder, highlights six issues with the tender offer. While Neuberger’s criticisms have merit, the Board could credibly refute most of them. 
The probability of a bump is low, as Neuberger cannot block the tender, the offer is attractive on several measures, and ALSOK/Carlyle can use the playbook to counter activists.  


Nippon Dry-Chemical (1909 JP): Neuberger Starts an Activist Campaign, but Success Is Uncertain

<ul>
<li>
<a href="https://www.smartkarma.com/entities/nippon-dry-chemical-co-ltd" target="_blank" data-smartkarma-citation="entities:13528:1" rel="noopener">Nippon Dry Chemical (1909 JP)</a> announced a tender offer from Alsok (2331 JP) and <a href="https://www.smartkarma.com/entities/carlyle-group-inc-the" target="_blank" data-smartkarma-citation="entities:33402:1" rel="noopener">Carlyle Group / (CG US)</a> at JPY3,730, a 23.3% premium to the last close. </li>
<li>Alsok and Carlyle initially engaged in a bidding war but eventually settled on a joint bid. Post-squeezeout, Alsok and Carlyle will hold 51% and 49% of BidCo's voting rights, respectively.</li>
<li>The offer is attractive, as it represents an all-time high and sits at the high end of the target IFA’s DCF valuation range. This is a done deal. </li>
</ul>



Nippon Dry Chemical (1909 JP) announced a tender offer from Alsok (2331 JP) and Carlyle Group / (CG US) at JPY3,730, a 23.3% premium to the last close. 
Alsok and Carlyle initially engaged in a bidding war but eventually settled on a joint bid. Post-squeezeout, Alsok and Carlyle will hold 51% and 49% of BidCo's voting rights, respectively.
The offer is attractive, as it represents an all-time high and sits at the high end of the target IFA’s DCF valuation range. This is a done deal. 


Nippon Dry Chemical (1909 JP): Alsok/Carlyle Tender Offer at JPY3,730

Analyst

Alasdair Moody

Exposing Creative Accounting

Bucephalus Research Partnership

Bucephalus Research Partnership Limited. Exposing Creative Accounting.

At the Bucephalus Research Partnership (BRP) we analyse financial statements using our accountant's practical experience and our own quantitative algorithms for corporate governance, accounting risk and peer performance.

Our thematic research refines our unique algorithms while our single stock research focuses on examples where we discover a significant gap between published accounts and business reality.

​Bucephalus Research Partnership:
- Is an independent fee-based research service
- Does not take proprietary positions, long or short
- Does not solicit business or fees from the corporates we review

Thematic (Sector/Industry)

We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created statistics for each region based on aggregate data and for a typical company. In this trend report, we summarise the data and highlight the outliers. Assuming clients will have their own macro industry views, we used valuations and our Governance, Accounting risk and Peer performance (GAP) scores, (which help quantify the risk of creative accounting) to…

We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created statistics for each region based on aggregate data and for a typical company. In this trend report, we summarise the data and highlight the outliers. Assuming clients will have their own macro industry views, we used valuations and our Governance, Accounting risk and Peer performance (GAP) scores, (which help quantify the risk of creative accounting) to…

Global Pharmaceuticals: Valuations, Assets and Leverage Up - Margins Down

Japan Specialist

Mark Chadwick

Equity Bottom-Up

Teikoku Sen-i Co., Ltd. / Equity Bottom-Up

<ul>
<li>Teikoku, a stable disaster equipment leader, is undervalued due to excessive cash and cross-holdings.  </li>
<li>Regulatory pressure, industry trends, and potential Hulic asset sales create an opportunity to unlock hidden value.</li>
<li>Despite fair current pricing, potential share repurchases and improved capital allocation offer up to 40% upside.</li>
</ul>


Teikoku, a stable disaster equipment leader, is undervalued due to excessive cash and cross-holdings.  
Regulatory pressure, industry trends, and potential Hulic asset sales create an opportunity to unlock hidden value.
Despite fair current pricing, potential share repurchases and improved capital allocation offer up to 40% upside.


Hidden Value in Plain Sight: Teikoku's (3302) Potential Unlock

Japan

TEIKOKU SEN-I Co., Ltd. produces flame-retardant and heat-resistant synthetic fibers.  The Company uses its technologies to make disaster-prevention equipment such as fire hoses, firefighter's uniforms, and rescue vehicles.  Teikoku Sen-i also manufactures and sells linen yarns and textile products made from linen synthetic fibers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Teikoku Sen-i Co., Ltd. (3302 JP)

Screening the Silk Road: Q1 2021 All Cap Screening - Free Cashflow (FCF)

With the value/growth investment style ratio at 20-year lows, we present 27 names which hold characteristics worthy of further review.

David Lepper

Nippon Dry-Chemical (1909 JP): Neuberger Starts an Activist Campaign, but Success Is Uncertain

While Neuberger’s criticisms have merit, the Board could credibly refute most of them. The shares are marginally trading through terms, but the...

Arun George

Nippon Dry Chemical (1909 JP): Alsok/Carlyle Tender Offer at JPY3,730

Alsok and Carlyle initially engaged in a bidding war but eventually settled on a joint bid. The offer is attractive and sits at the high end of the...

Arun George

Global Pharmaceuticals: Valuations, Assets and Leverage Up - Margins Down

We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created...

Bucephalus Research Partnership

Hidden Value in Plain Sight: Teikoku's (3302) Potential Unlock

Teikoku, a disaster equipment leader, is undervalued due to excess cash and cross-holdings. Regulatory pressure and potential asset sales could...

Mark Chadwick

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Screening the Silk Road: Q1 2021 All Cap Screening - Free Cashflow (FCF)

With the value/growth investment style ratio at 20-year lows, we present 27 names which hold characteristics worthy of further review.

David Lepper

Nippon Dry-Chemical (1909 JP): Neuberger Starts an Activist Campaign, but Success Is Uncertain

While Neuberger’s criticisms have merit, the Board could credibly refute most of them. The shares are marginally trading through terms, but the...

Arun George

Nippon Dry Chemical (1909 JP): Alsok/Carlyle Tender Offer at JPY3,730

Alsok and Carlyle initially engaged in a bidding war but eventually settled on a joint bid. The offer is attractive and sits at the high end of the...

Arun George

Global Pharmaceuticals: Valuations, Assets and Leverage Up - Margins Down

We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created...

Bucephalus Research Partnership

Hidden Value in Plain Sight: Teikoku's (3302) Potential Unlock

​Teikoku, a disaster equipment leader, is undervalued due to excess cash and cross-holdings. Regulatory pressure and potential asset sales could...

Mark Chadwick

Teikoku, a disaster equipment leader, is undervalued due to excess cash and cross-holdings. Regulatory pressure and potential asset sales could...